Associated Papers
The genomic and transcriptomic landscape of metastastic urothelial cancer.
Loriot Y et al.
Nature Communications, 2024
39366934 (PubMed )
Supplement: 41467_2024_52915_MOESM9_ESM.xlsx › SuppTable6_mMIBC-Somatic_alt
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes.
Noerenberg D et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2024
38055913 (PubMed )
Supplement: DS3_JCO.23.01053.xlsx › Table_S2.2
All-CLL: A Capture-based Next-generation Sequencing Panel for the Molecular Characterization of Chronic Lymphocytic Leukemia.
López-Oreja I et al.
Hemasphere, 2023
37746159 (PubMed )
Supplement: hs9-7-e962-s002.xlsx › Table_S6
Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.
Gao F et al.
Cancer Medicine, 2023
36971051 (PubMed )
Supplement: CAM4-12-10267-s001.xlsx › Sheet1
Distinct p53 phosphorylation patterns in chronic lymphocytic leukemia patients are reflected in the activation of circumjacent pathways upon DNA damage.
Mancikova V et al.
Molecular Oncology, 2023
36334078 (PubMed )
Supplement: MOL2-17-82-s003.pdf
Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.
Frauenfeld L et al.
Blood Advances, 2022
34654055 (PubMed )
Supplement: advancesADV2021006034-suppl1.pdf
Recurrent mutations in topoisomerase IIα cause a previously undescribed mutator phenotype in human cancers.
Boot A et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
35058360 (PubMed )
Supplement: pnas.2114024119.sd08.xlsx › Dataset.S8
T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.
Wang J et al.
Frontiers in Immunology, 2022
35572515 (PubMed )
Supplement: Table_2.xlsx › S5
MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.
Ramis-Zaldivar JE et al.
Haematologica, 2021
33951889 (PubMed )
Supplement: 2020_271957_RAMIS-ZALDIVAR_SUPPL_TableS5.xlsx › 194_Mutations
Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia.
Jiménez I et al.
Biomarker Research, 2021
34016160 (PubMed )
Supplement: 40364_2021_290_MOESM1_ESM.zip › renamed_27ef3.xlsx › Suplementary_table_3
Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.
Li P et al.
Frontiers in Oncology, 2021
33747936 (PubMed )
Supplement: Data_Sheet_1.xlsx › Table_2
Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.
Gao F et al.
Frontiers in Genetics, 2021
34925435 (PubMed )
Supplement: DataSheet2.xlsx › Sheet1
Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study.
Jeong S et al.
Scientific Reports, 2020
32770099 (PubMed )
Supplement: 41598_2020_70310_MOESM1_ESM.pdf
Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma.
Zhang W et al.
Bmc Cancer, 2020
32736575 (PubMed )
Supplement: 12885_2020_7198_MOESM5_ESM.xlsx › Table_S3
Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease.
Rose-Zerilli MJ et al.
Leukemia, 2016
26847028 (PubMed )
Supplement: leu201610x6.xls › 2015_RoseZerilli_WES_in_IGHVmut
Acquired initiating mutations in early hematopoietic cells of CLL patients.
Damm F et al.
Cancer Discovery, 2014
24920063 (PubMed )
Supplement: 21598290cd140104-sup-tab1.xls › CLL08_
Select a paper to view details